American Society of Hirudotherapy

Hirunipin-2 — Second-Generation Leech Antimicrobial Peptide

Expanded characterization of hirunipin family with enhanced antimicrobial spectrum

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Antimicrobial ResistanceSalivary PharmacologyDrug DevelopmentKumar et al. · Advanced Science (Wiley), 2025

Summary

Extended characterization of hirunipin-2, a second member of the hirunipin antimicrobial peptide family from Hirudo medicinalis. Features an expanded antimicrobial spectrum compared to the prototype, including activity against additional Gram-negative pathogens and enhanced biofilm penetration.

Why This Matters for Hirudotherapy

Demonstrates that the hirunipin AMP family contains multiple variants with potentially optimizable properties. The structural diversity within a single leech peptide family supports rational drug design approaches to engineering improved antimicrobial agents.

Citation

Novel Antimicrobial Peptides from Hirudo medicinalis — Hirunipins

Kumar et al. · Advanced Science (Wiley), 2025

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Hirunipin-2 — Second-Generation Leech Antimicrobial Peptide | ASH